Last reviewed · How we verify
NCT06167330: TITAN
TITAN Trial: Reducing Phantom Limb Pain in People with Amputations
NA trial testing Progressive rehabilitation program in Phantom Limb Pain in 208 participants. Currently enrolling.
18 December 2026
Quick facts
| Lead sponsor | Neuroscience Research Australia |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 208 |
| Start date | 18 December 2023 |
| Primary completion | 18 December 2026 |
| Estimated completion | 18 December 2027 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Progressive rehabilitation program
- Stimulation devices
Conditions studied
- Phantom Limb Pain — all drugs for Phantom Limb Pain →
- Amputation — all drugs for Amputation →
Sponsor
Neuroscience Research Australia
Who can join
18 and older, any sex, with Phantom Limb Pain or Amputation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to investigate the effectiveness of two rehabilitation programs for individuals who have undergone amputations and are experiencing phantom limb pain. The main question it aims to answer is: \- In individuals who have undergone amputations and are experiencing phantom limb pain, what is the effectiveness of a progressive rehabilitation program compared to a treatment program consisting of transcutaneous electrical nerve stimulation and cranial electrical stimulation on reducing pain intensity and pain interference? A total of 208 participants will be randomized into two groups: progressive rehabilitation program and stimulation devices. The progressive rehabilitation program includes pain science education, sensory training, and left/right judgements, imagined movements and mirror therapy. The treatment program for the group receiving the stimulation devices includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Both interventions will be delivered via eight, up to 1-hour telehealth sessions. Outcome measures will be assessed at baseline and weeks 12, 24 and 52.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06167330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Phantom Limb Pain
Currently open trials in the same condition.
- NCT07401966 — Amputations in Childhood and Neuropathic Pain · recruiting
- NCT06719245 — Prevention of PostAmputation Pain With Targeted Muscle Reinnervation · NA · recruiting
- NCT06702904 — Evaluation of Neuroprosthesis with Sensory Feedback for Modulation of Phantom Limb Pain and Enhancing Quality of Life · NA · recruiting
- NCT06813937 — Peripheral Magnetic Stimulation (PMS) Effects on Somatosensory Perception in Patients with Upper Limb Amputation · NA · recruiting
- NCT06644807 — Study of Phantom Limb Pain Suppression Using Neuromodulation Methods · NA · recruiting
Other Neuroscience Research Australia trials
Trials by the same sponsor.
- NCT07205991 — ADHERE Trial: Strategies to Improve Mobile App Adherence · NA · recruiting
- NCT06620133 — Pain Education and Patient-led Goal Setting in Adults With Chronic Low Back Pain: a Randomised Controlled Trial · NA · recruiting
- NCT06984354 — Digitally Delivered Treatments to Reduce Chronic Low Back Pain · NA · recruiting
- NCT06605248 — NOTUS Feasibility Study: Reducing Chronic Low Back Pain With Mobile App Intervention · NA · completed
- NCT06535646 — Digital Health Technology for People With Mitochondrial Disease · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06167330 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Neuroscience Research Australia
- Last refreshed: 5 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06167330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing